Manager II, Clinical Trials
Tarsus Pharamceuticals$60,000 - $80,000/year
- Full Time
- Mid-level (3 to 4 years), Senior (5 to 8 years)
About Tarsus Pharamceuticals
Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company is also working on other potential treatments for conditions such as Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong pipeline of future products. Their goal is to provide effective treatments for patients suffering from these conditions while ensuring compliance with regulations and ethical standards.
Irvine, CaliforniaHeadquarters
2017Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget
Risks
Increased competition in ophthalmic treatments challenges Tarsus's market position.
Potential clinical trial delays could affect Tarsus's product pipeline.
Supply chain constraints may hinder XDEMVY's production and distribution.
Differentiation
Tarsus focuses on high unmet needs in ophthalmic and infectious diseases.
Their lead product, XDEMVY, is FDA-approved for Demodex blepharitis treatment.
Tarsus's pipeline includes innovative treatments for Lyme disease and Rosacea.
Upsides
Growing awareness of Demodex blepharitis expands market for Tarsus's XDEMVY.
Telemedicine rise offers new marketing opportunities for Tarsus's products.
FDA's focus on unmet needs may expedite Tarsus's pipeline approvals.
Funding
Total raised$58.36 M
Latest valuation$308.00 M
StageIPO
POST IPO DEBT
3/31/2024$75
POST IPO EQUITY
1/31/2024$100
IPO
9/30/2020$88
$308.00 M$60
$300.00 M